Patients with brain cancer, including one patient from Peterborough, have voiced their disappointment after a drug that slows or even halts tumour growth was rejected for use on the NHS . The National Institute for Health and Care Excellence (Nice) has issued draft guidance rejecting vorasidenib due to uncertainties in the economic data and lack of clarity on whether the drug improves overall survival.

Vorasidenib is intended for individuals aged 12 or over who have undergone surgery for types of low-grade glioma with either the IDH1 or IDH2 genetic mutations. Patients who have used the drug in clinical trials report remarkable results, including shrinkage of their tumours.

IDH-mutant low-grade gliomas are one of the most common primary brain tumours diagnosed in people under 50 and ar

See Full Page